Their pace of annual increase in per capita spending on medicines in Purchasing power parity (PPP) terms is 20% faster in Eastern Europe compared to their Western counterparts, creating an opportunity for new biotech organizations to enter.

During the same years, EEC region expanded their pharmaceuticals share of health spending at an eight-fold faster annual rate compared to the EU.

​Private (Sick Funds, Named-Patients Use) and out-of-pocket expenditure became dominant in EEC, thus a trustworthy partner with wide experience in Market Access is needed for a successful product introduction.